NVCR
NasdaqNovoCure Limited
Technology · Surgical & Medical Instruments & Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$535.0M
2021
$537.8M
2022
$509.3M
2023
$605.2M
2024
$655.4M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$655.4M
Net Income$-136.2M
Gross Profit$488.5M
Oper Income$-153.8M
EPS (dil)$-1.22
Rev/sh$5.66
FCF/sh$-0.65
Book/sh$2.94
Gross M74.5%
Oper M-23.5%
Profit M-20.8%
FCF M-11.5%
ROE-40.0%
ROA-16.9%
ROIC-35.6%
R&D/Rev34.3%
Rev Y/Y8.3%
Rev 3Y CAGR6.8%
EPS Y/Y21.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout0%
Div/sh—
Shs Chg Y/Y+3.4%
Current Ratio2.90
Quick Ratio2.71
Debt/Eq0.57
Int Coverage-6.9×
Net Debt$91.7M
Total Debt$195.0M
Cash & Eq$103.4M
Total Assets$804.3M
Oper CF$-49.0M
Capex$26.6M
Free CF$-75.7M
Buybacks$5,000
Equity$340.5M
Liabilities$463.9M
Shs Outstand0.12B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Gross Profit | $420.2M | $423.0M | $381.1M | $468.0M | $488.5M |
| Operating Income | $-44.3M | $-89.5M | $-232.9M | $-170.5M | $-153.8M |
| Net Income | $-58.0M | $-93.0M | $-207.0M | $-169.0M | $-136.2M |
| Diluted EPS | $-0.56 | $-0.88 | $-1.95 | $-1.56 | $-1.22 |
| Operating Cash Flow | $82.8M | $30.8M | $-73.3M | $-26.4M | $-49.0M |
| Free Cash Flow | $58.6M | $9.4M | $-100.4M | $-69.2M | $-75.7M |
COMMUNITY · $NVCR0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.